Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02418754 · ClinicalTrials.gov registry record · Phase 2
Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)
A Phase 2 study, sponsored by Regeneron Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 505
- Enrollment target
NCT02418754 is a Phase 2 study that was terminated before completion, run by Regeneron Pharmaceuticals. The registered enrollment target is 505 participants.
The verdict
NCT02418754, a Phase 2 study, was terminated before completion, sponsored by Regeneron Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 505 participants
- Enrollment target
Study Summary
The primary objective of the study was to explore the effect of REGN2176-3 on the Early Treatment Diabetic Retinopathy Scale (ETDRS) best-corrected visual acuity (BCVA) in participants with neovascular age-related macular degeneration (AMD), compared to intravitreal aflibercept injection (IAI) monotherapy. The secondary objectives of the study were the following: * To explore the effect of 2 dose levels of IVT REGN2176-3 on anatomical changes of CNV in participants with nAMD compared to IAI monotherapy (at week 12) * To evaluate if short-term treatment with REGN2176-3 followed by IAI monotherapy offered the same or additional benefit compared to continuous treatment with REGN2176-3. Also to determine if there was benefit in initiating IAI treatment prior to REGN2176-3 compared to continuous treatment with IAI. * To assess the safety and tolerability of IVT REGN2176-3 in participants with nAMD
Interventions
- DRUG Intravitreal Aflibercept Injection (IAI)
- DRUG REGN2176-3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 505 participants |
| Start Date | 2015-05-05 |
| Est. Completion | 2017-04-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02418754
The ClinicalTrials.gov registry entry for NCT02418754 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 505 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Intravitreal Aflibercept Injection (IAI) is the first listed.
NCT02418754 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02418754 about?
NCT02418754 is a clinical study titled "Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)". The primary objective of the study was to explore the effect of REGN2176-3 on the Early Treatment Diabetic Retinopathy Scale (ETDRS) best-corrected visual acuity (BCVA) in participants with neovascular age-related macular degeneration (AMD), compared to intravitreal aflibercept injection (IAI) monot...
What is the current status of trial NCT02418754?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 505 participants. The study started on 2015-05-05. Estimated completion is 2017-04-03.
What interventions are being tested in trial NCT02418754?
The interventions under investigation include: Intravitreal Aflibercept Injection (IAI) (DRUG), REGN2176-3 (DRUG).
Who is sponsoring clinical trial NCT02418754?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.